Aescap logo

It's all about People

Supervision Aescap 2.0

Aescap 2.0 works with a proven Dutch model of a so called mutual fund, known in Dutch as FGR (Fonds voor Gemene Rekening), in which in fact the fund is owned by all investors together. We have chosen to focus ourselves on making the right investments and have therefore outsourced all administrative matters.
The management of the fund entity, the Aescap 2.0 Foundation, as well as the administration of the participants is performed by a renowned trust office, the SGG Group. SGG is also responsible for our financial reporting and calculates the NAV (Net Asset Value) on a monthly basis. The auditing of the annual accounts is done by a top 10 auditor, Mazars. Furthermore, the fund has an Investor’s Committee, that supervises the fund manager, and consists of representatives of the investors in the fund. The fund is 100% ‘tax transparant’.

 

Fund Structure Aescap 2.0:

 

Investors Committee

Peter Jan Rubingh

Peter Jan Rubingh

Peter Jan has more than 35 years of experience in investing. In different disciplines, in almost all asset classes, and in good and bad times. From 1979 – 1993 Peter Jan has been working at the Noro Group of Companies, then from 1993 – 2008 at both his own company TPR & Partenrs and at W.P. Stewart & Co, thereafter from 2009 – 2013 at Oyens & Van Eeghen. Peter Jan is independent since 2014 and mainly active as an involved and dedicated investor.

 

Michaël Mellink

Michaël Mellink is the Managing Partner of the Amsterdam office of Odgers Berndtson executive search firm where he is also Head of the Life Sciences and Fast Moving Consumer Goods Practices. He works across all functional disciplines with an emphasis on CEO/MD, CFO, Senior Commercial and Human Resources appointments. Next to this he is since 2011 Board member of Odgers Berndtson International.

Prior to joining Odgers Berndtson, he worked for Cephalon, a U.S. biopharmaceutical company, where he was General Manager for the initial establishment of the Benelux office and operations as well as for European Business Development. He also worked for Eli Lilly and Company in senior commercial and management positions. Michaël holds a Bachelor’s degree in Physiotherapy and studied next to this Orthopedic Medicine.